Today, biologics represent a $250 billion industry, which is two times what it was worth only 10 years ago. Though monoclonal antibodies are expected to continue dominating the market, a more diversified pipeline that includes, for example, DNA and RNA molecules and cell and gene therapies, is anticipated as the growth continues. Responding to the rapidly changing requirements of these novel therapies means tackling some of the biggest challenges that have the potential to hinder this evolution. One such area is security in the biopharmaceutical supply chain, which has become a far more complex topic.
January 16, 2020